Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538343 · ClinicalTrials.gov registry record · Phase 2
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00538343 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 14 participants.
The verdict
NCT00538343, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
Interventions
- DRUG berubicin hydrochloride (RTA 744)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-10-31 |
| Est. Completion | 2009-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00538343
The ClinicalTrials.gov registry entry for NCT00538343 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which berubicin hydrochloride (RTA 744) is the first listed.
NCT00538343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00538343 about?
NCT00538343 is a clinical study titled "RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases". The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
What is the current status of trial NCT00538343?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-10-31. Estimated completion is 2009-01-01.
What interventions are being tested in trial NCT00538343?
The interventions under investigation include: berubicin hydrochloride (RTA 744) (DRUG).
Who is sponsoring clinical trial NCT00538343?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.